Literature DB >> 9860192

Ventricular repolarization time indexes following anthracycline treatment.

B Sarubbi1, M Orditura, V Ducceschi, F De Vita, L Santangelo, F Ciaramella, G Catalano, A Iacono.   

Abstract

The anthracyclines, doxorubicin and daunorubicin, are antibiotics effective in the treatment of many malignancies. However, their usefulness is limited by the development of potentially fatal cardiotoxicity. Cardiac monitoring by a noninvasive test capable of identifying patients at high risk of cardiac damage, before the ejection fraction deteriorates would have clinical utility. Electrocardiograms and echocardiograms are routinely utilized for noninvasive assessment of myocardial function. However, of the ECG abnormalities described, none has been noted to be of consistent predictive value for cardiotoxicity. The aim of this study was to assess the effects of doxorubicin on ventricular repolarization time indexes, as they have been shown to be effective in the identification of electrical myocardial instability and, hence, in the identification of risk for either arrhythmia or heart failure. For this reason, electrocardiograms were compared in 35 cancer patients at the first presentation (drug-free state) and after 29.4 +/- 37.65 weeks of treatment with doxorubicin. The results of the present study showed that after only a short period of treatment with doxorubicin there was a significant increase in ventricular recovery time dispersion indexes (QTc, JT, and JTc dispersion, and their "adjusted" values). Thus, increased regional variation in ventricular repolarization could be, in the absence of a significant modification of the echocardiographic parameters, an early marker of an electropathy, due to the early cardiotoxic action of doxorubicin on myocardial cells, eventually leading to heart failure.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9860192     DOI: 10.1007/bf02766801

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  35 in total

1.  Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer.

Authors:  A M Goorin; A R Chauvenet; A R Perez-Atayde; J Cruz; R McKone; S E Lipshultz
Journal:  J Pediatr       Date:  1990-01       Impact factor: 4.406

2.  Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group.

Authors:  L J Steinherz; T Graham; R Hurwitz; H M Sondheimer; R G Schwartz; E M Shaffer; G Sandor; L Benson; R Williams
Journal:  Pediatrics       Date:  1992-05       Impact factor: 7.124

3.  QT interval prolongation as predictor of sudden death in patients with myocardial infarction.

Authors:  P J Schwartz; S Wolf
Journal:  Circulation       Date:  1978-06       Impact factor: 29.690

4.  Risk factors for doxorubicin-induced congestive heart failure.

Authors:  D D Von Hoff; M W Layard; P Basa; H L Davis; A L Von Hoff; M Rozencweig; F M Muggia
Journal:  Ann Intern Med       Date:  1979-11       Impact factor: 25.391

5.  Mechanism of ventricular arrhythmias caused by increased dispersion of repolarization.

Authors:  C S Kuo; C P Reddy; K Munakata; B Surawicz
Journal:  Eur Heart J       Date:  1985-11       Impact factor: 29.983

6.  Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography.

Authors:  R G Schwartz; W B McKenzie; J Alexander; P Sager; A D'Souza; A Manatunga; P E Schwartz; H J Berger; J Setaro; L Surkin
Journal:  Am J Med       Date:  1987-06       Impact factor: 4.965

7.  QT dispersion in nonsustained ventricular tachycardia and coronary artery disease.

Authors:  F Bogun; K K Chan; M Harvey; R Goyal; M Castellani; M Niebauer; E Daoud; K C Man; S A Strickberger; F Morady
Journal:  Am J Cardiol       Date:  1996-02-01       Impact factor: 2.778

8.  Correlation between late potentials duration and QTc dispersion: Is there a causal relationship?

Authors:  V Ducceschi; B Sarubbi; A Giasi; B Russo; P Lucca; L Santangelo; M Giasi; A Iacono
Journal:  Int J Cardiol       Date:  1996-03       Impact factor: 4.164

9.  Dispersion of ventricular repolarization and arrhythmic cardiac death in coronary artery disease.

Authors:  W Zareba; A J Moss; S le Cessie
Journal:  Am J Cardiol       Date:  1994-09-15       Impact factor: 2.778

Review 10.  New anthracycline antitumor antibiotics.

Authors:  F M Muggia; M D Green
Journal:  Crit Rev Oncol Hematol       Date:  1991       Impact factor: 6.312

View more
  4 in total

1.  Assessment of early-onset chronic progressive anthracycline cardiotoxicity in children: different response patterns of right and left ventricles.

Authors:  Abdullah Kocabaş; Fırat Kardelen; Halil Ertuğ; Bilge Aldemir-Kocabaş; Özgür Tosun; Akif Yeşilipek; Volkan Hazar; Gayaz Akçurin
Journal:  Pediatr Cardiol       Date:  2013-07-03       Impact factor: 1.655

2.  Repolarization effects of multiple-cycle chemotherapy and predictors of QTc prolongation: a prospective female cohort study on >2000 ECGs.

Authors:  Igor Diemberger; Giulia Massaro; Marta Cubelli; Daniela Rubino; Sara Quercia; Cristian Martignani; Matteo Ziacchi; Mauro Biffi; Alessandra Bernardi; Nicoletta Cacciari; Claudio Zamagni; Giuseppe Boriani
Journal:  Eur J Clin Pharmacol       Date:  2015-06-02       Impact factor: 2.953

3.  The influence of type 2 diabetes and gender on ventricular repolarization dispersion in patients with sub-clinic left ventricular diastolic dysfunction.

Authors:  Ylber Jani; Ahmet Kamberi; Sotir Xhunga; Bekim Pocesta; Fatmir Ferati; Dali Lala; Agim Zeqiri; Atila Rexhepi
Journal:  Am J Cardiovasc Dis       Date:  2015-10-12

4.  Long QT syndrome and torsade de pointes after anthracycline chemotherapy.

Authors:  N Colombo; M Civelli; D Cardinale; G Lamantia; A Colombo; G De Giacomi; C Cipolla
Journal:  Ecancermedicalscience       Date:  2009-06-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.